ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ • Healthcare

$4.03

-$0.29 (-6.7%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$4.28

Previous Close$4.03

Day Range$4 - $4.28

Avg. Volume (3M)1.5M

Market Cap$400.7M

52 Week Range

$3.81$13.15

Next EarningsIn 15 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$33.6M100%

Gross Profitminus cost of goods$20.8M62%

Fundamentals & Financials

Revenue (TTM)

$116.9M

Net Income (TTM)

-$215.4M

EPS (TTM)

-$2.18

ROA (TTM)

-86.35%

Current Ratio

3.48

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-12.2%Q3 2025-$0.46

-15.6%Q4 2025-$0.52

0.0%Q1 2026-$0.42

-15.1%Q2 2026-$0.61

-31.9%Q3 2026-$0.63

Nov 9

in 15 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

ARS Pharmaceuticals, Inc. (SPRY) reports on November 9, 2026. Wall Street expects EPS of -$0.33 on revenue of $42.8 million. For trailing context, revenue grew +114.2% year over year last quarter. SPRY has beaten EPS in 1 of 8 most recent quarters, making expectations a key focus.

View full earnings history

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. develops nasal-spray treatments in biotechnology and trades on the NASDAQ as SPRY. Its business centers on intranasal epinephrine products for severe allergic reactions, and it recorded $84.3 million of revenue in FY2025. The company was founded in 2015 and is based in San Diego, California.

Name

ARS Pharmaceuticals, Inc.

CEO

Donn Casale

Website

ars-pharma.com

Industry

Healthcare

Year Founded

2015

Employees

195

Today's Snapshot

AI-generated

The day ended with SPRY 6.7% lower at 4.03, in line with a weaker sector.

Trading Volume

Below 10d avg (1.6M)

1.5M

vs S&P 500 Today

Strong Underperformance

-6.19%

Updated: October 23, 2026 at 20:22 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

SPRY is positioned under its short- and longer-term moving averages and the technical setup favors sellers, with modest negative momentum and a subdued MACD reflecting limited bullish pressure. The ADX is lowish, suggesting the down move lacks strong trend momentum, yet ATR is relatively high as a percentage of price, indicating notable intraday variability, and on-balance volume is deeply negative which supports selling pressure. The pivot around 4.27 lies above the current level and may provide resistance. Technical takeaway: Strong Sell.

All signals

EMA (5 indicators)$4.17 - $7.17
Sell
RSI (14)41.38
Neutral
Stochastic %K (14, 3, 3)44.18
Neutral
MACD Level (12, 26)-0.16
Neutral

Peers & Related Assets

XERSXeris Biopharma Holdings, Inc.

$10.2-6.1%

MNKDMannKind Corporation

$3.19-0.3%

AQSTAquestive Therapeutics, Inc.

$4-3.1%

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.